ALT Altimmune Inc
Price (delayed)
$4.74
Market cap
$365.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.34
Enterprise value
$328.08M
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
Highlights
Altimmune's EPS has increased by 19% YoY and by 15% QoQ
Altimmune's net income has increased by 8% QoQ but it has decreased by 7% YoY
ALT's revenue has dropped by 95% year-on-year and by 62% since the previous quarter
The gross profit has plunged by 95% YoY and by 62% from the previous quarter
Key stats
What are the main financial stats of ALT
Market
Valuations
Earnings
Shares outstanding
77.01M
Market cap
$365.04M
Enterprise value
$328.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.73
Price to sales (P/S)
16,827.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16,403.84
Revenue
$20,000
Gross profit
$20,000
Operating income
-$103.17M
Net income
-$95.06M
EBIT
-$95.05M
EBITDA
-$94.81M
Free cash flow
-$79.85M
Per share
Balance sheet
Liquidity
EPS
-$1.34
EPS diluted
-$1.34
Free cash flow per share
-$1.12
Book value per share
$1.74
Revenue per share
$0
TBVPS
$1.96
Total assets
$139.31M
Total liabilities
$15.8M
Debt
$0
Equity
$123.51M
Working capital
$126.79M
Debt to equity
0
Current ratio
13.11
Quick ratio
12.66
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-474,060%
Gross margin
100%
Net margin
-475,295%
Operating margin
-515,860%
Return on assets
-58.6%
Return on equity
-65.3%
Return on invested capital
-95.4%
Return on capital employed
-73.8%
Return on sales
-475,250%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALT stock price
How has the Altimmune stock price performed over time
Intraday
-5.2%
1 week
-19.52%
1 month
-28.72%
1 year
-53.67%
YTD
-34.26%
QTD
-5.2%
Financial performance
How have Altimmune's revenue and profit performed over time
Revenue
$20,000
Gross profit
$20,000
Operating income
-$103.17M
Net income
-$95.06M
Gross margin
100%
Net margin
-475,295%
The operating margin has dropped by 140% since the previous quarter
The net margin has dropped by 139% since the previous quarter
ALT's revenue has dropped by 95% year-on-year and by 62% since the previous quarter
The gross profit has plunged by 95% YoY and by 62% from the previous quarter
Growth
What is Altimmune's growth rate over time
Valuation
What is Altimmune stock price valuation
P/E
N/A
P/B
2.73
P/S
16,827.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16,403.84
Altimmune's EPS has increased by 19% YoY and by 15% QoQ
The equity has declined by 36% year-on-year and by 7% since the previous quarter
The P/B is 22% lower than the last 4 quarters average of 3.7 but 20% higher than the 5-year quarterly average of 2.4
ALT's revenue has dropped by 95% year-on-year and by 62% since the previous quarter
ALT's P/S is 92% above its last 4 quarters average of 9225.3
Efficiency
How efficient is Altimmune business performance
Altimmune's return on sales has shrunk by 139% QoQ
The company's return on invested capital rose by 38% YoY and by 15% QoQ
The return on equity has declined by 26% year-on-year and by 3% since the previous quarter
ALT's ROA is down by 24% YoY
Dividends
What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Altimmune financials performed over time
The total assets has contracted by 34% YoY and by 6% from the previous quarter
Altimmune's current ratio has decreased by 24% YoY and by 22% from the previous quarter
The debt is 100% smaller than the equity
The equity has declined by 36% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.